29% at one year
As of early 2026, Retatrutide is in Phase 3 clinical trials, which is the final stage of testing before the developing company, Eli Lilly, can seek FDA approval
[2] [4] Retatrutide is administered as a subcutaneous injection , typically once weekly, in a manner similar to other GLP-1-based therapies
Discover Blooms Prescriptions: Tailored for You
Change Your Life Today For Only $249/month 4
has received fees for travel support, advisory boards and scientific presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, the Limbic, Janssen, Medscape, Novo Nordisk and Travere Therapeutics